[
  {
    "ts": null,
    "headline": "Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors?",
    "summary": "In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and commercialize cancer therapies based on a cell-surface target identified by DISCO’s proteomics and protein community mapping platform, with DISCO eligible for up to US$618 million in potential payments plus royalties. The deal gives Amgen access to a differentiated surfaceome-targeting engine that can inform bispecific antibody-drug conjugates and T‑cell engagers, potentially...",
    "url": "https://finnhub.io/api/news?id=13bc00a1ae3baa4ee5893b53374c2842ad00786ebeeb50dd31b702e219dc0a71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767888858,
      "headline": "Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors?",
      "id": 138038448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and commercialize cancer therapies based on a cell-surface target identified by DISCO’s proteomics and protein community mapping platform, with DISCO eligible for up to US$618 million in potential payments plus royalties. The deal gives Amgen access to a differentiated surfaceome-targeting engine that can inform bispecific antibody-drug conjugates and T‑cell engagers, potentially...",
      "url": "https://finnhub.io/api/news?id=13bc00a1ae3baa4ee5893b53374c2842ad00786ebeeb50dd31b702e219dc0a71"
    }
  },
  {
    "ts": null,
    "headline": "Can These Dividend Stocks Beat the Market Again in 2026?",
    "summary": "There is an even more important question to address.",
    "url": "https://finnhub.io/api/news?id=6be2c2017c81ceb01737309c6002eb1081fc8867449834c794fc9a51d37adb94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767880620,
      "headline": "Can These Dividend Stocks Beat the Market Again in 2026?",
      "id": 138036775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "There is an even more important question to address.",
      "url": "https://finnhub.io/api/news?id=6be2c2017c81ceb01737309c6002eb1081fc8867449834c794fc9a51d37adb94"
    }
  },
  {
    "ts": null,
    "headline": "Upstream Bio: Fully Priced After Recent Rally",
    "summary": "Upstream Bio, Inc. surged on Phase 2 verekitug data for CRSwNP, but revenue likely post-2030 and dilution risk remains. Click for more on UPB stock prospects.",
    "url": "https://finnhub.io/api/news?id=ea6b0946b33801fc42d573d7c7f62f7d8feed18e036f9db7e9f6d5d9f62097fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767872639,
      "headline": "Upstream Bio: Fully Priced After Recent Rally",
      "id": 138037586,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2009511438/image_2009511438.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Upstream Bio, Inc. surged on Phase 2 verekitug data for CRSwNP, but revenue likely post-2030 and dilution risk remains. Click for more on UPB stock prospects.",
      "url": "https://finnhub.io/api/news?id=ea6b0946b33801fc42d573d7c7f62f7d8feed18e036f9db7e9f6d5d9f62097fd"
    }
  }
]